CX 2026 Registration
CX Executive Board
CX 2026 Programme
CX 2026 – The 48th Charing Cross Symposium
The Charing Cross (CX) Symposium continues to set the standard in vascular and endovascular education, shaping the future of practice worldwide. CX 2026 marked the final chapter of our current three-year cycle, designed to spark debate on the biggest controversies in the field. Our distinguished faculty of global experts critically examined the evidence, exchanged perspectives, and worked towards building consensus on the issues that matter most.
Consensus was the defining theme for CX 2026. We welcomed an international community of specialists, educators, and innovators to tackle the pressing challenges in vascular and endovascular medicine—challenges that directly impact patient outcomes and clinical decision-making.
In 2024, CX found a new home at ExCeL London, unlocking fresh opportunities for immersive, hands-on learning. The expanded workshop programme has gone from strength to strength, offering delegates practical skills alongside groundbreaking evidence and innovation. In 2026, we returned once again to London’s premier conference and exhibition venue to deliver an agenda packed with cutting-edge science, expert debate, and future-shaping education.
Stay connected—sign up for the CX Newsletter and be the first to hear the latest updates.
CX Co-Chairs
Latest CX news
CX 2018: Landmark EVRA trial provides first Level 1 evidence for early endovenous ablation
The first full results of the Early Venous Reflux Ablation (EVRA) ulcer study were presented at the Charing Cross Symposium yesterday. The presentation was accompanied by simultaneous publication in the New England Journal of [...]
Majority of CX audience decides endovascular-first strategy for critical limb ischaemia is a concept without evidence
At the CX Great Debate held yesterday, vascular and endovascular surgery titans went head-to-head to debate the contentious topic “Endovascular-first strategy for critical limb ischaemia is a concept without evidence”. Arguing in favour of [...]
Drug-coated balloon is “highly effective and safe” and shows outstanding clinical improvement for patients compared to an uncoated balloon
Ulf Teichgraeber The 12-month results from the full clinical cohort of the EffPAC randomised controlled trial, were presented for the first time at the CX Symposium yesterday. Target lesion revascularisation at 12 [...]